News | December 07, 2010

Bioresorbable Stent Overinflates Without Cracking or Crazing


December 7, 2010 – A new bioresorbable stent scaffold can be overinflated by more than 25 percent without cracking or crazing. New data from Arterial Remodeling Technologies (ART) show that its bioresorbable polylactic acid (PLA) stent platform is designed to avoid malapposition.

With conventional stents a gap between the vessel and the stent can manifest. This "malapposition" of stent struts within the vessel has been shown to occur in conventional stent placements and is a significant risk factor in stent thrombosis. Additionally, data on other bioresorbable stents showed that when the struts have been overinflated to compensate for potential malapposition, they have cracked or crazed. This may lead to a life-threatening coronary event.

The company’s stent is designed to have a faster and smoother resorption; a non-crystalline polymer; better, homogeneous stress diffusion; and crack- and crazing-free expansion. In addition, the device is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility.

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now